Skip to main content

Vicente Bebia Conesa

Medical Degree (Universidad de Murcia). Specialist in Gynecology and Obstetrics (Hospital 12 de Octubre, 2018). Gynecologic Oncologist (Vall d'Hebron, endorsed by ESGO).

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca
Doctor
Ginecologia Oncològica i Patologia del Tracte Genital Inferior
Children's Hospital and Woman's Hospital

Vicente Bebia Conesa

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca
Doctor
Ginecologia Oncològica i Patologia del Tracte Genital Inferior
Children's Hospital and Woman's Hospital

Medical Degree (Universidad de Murcia). Specialist in Gynecology and Obstetrics (Hospital 12 de Octubre, 2018). Gynecologic Oncologist (Vall d'Hebron, endorsed by ESGO).

I was born in Cartagena (Spain) in 1989. I completed my Medical Degree at Universidad de Murcia (Class 2007-2013). Via MIR, I finished the residency program in Obstetrics and Gynecology at Hospital 12 de Octubre (Madrid), where my interest in the surgical treatment of gynecological neoplasms began. After a brief period as a specialist at Hospital 12 de Octubre, I moved to Barcelona to pursue the Fellowship program in Gynecological Oncology at Vall d'Hebron. Currently, and after obtaining the Gynecologic Oncologist diploma endorsed by the European Society of Gynecology Oncology (ESGO), I work at the Gynecology Oncology Unit of Vall d'Hebron.
Along with the daily surgical activity, I do research as a member of the Gynecology Biomedical Research Group at VHIR. My main interests lie in the management and diagnosis of lymph node involvement in gynecological neoplasms (both clinically and surgically), as well as searching for new surgical methods for the treatment of tumors of gynecological origin.

Projects

Desarrollo de CEMARK-Px, un método in vitro para el diagnóstico objetivo y preciso del tipo y grado histológico del cáncer de endometrio en fluido uterino

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melek Denizli, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 278300
Reference: DTS23/00091
Duration: 01/01/2024 - 31/12/2025

xx

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Ana Luzarraga Aznar, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 177500
Reference: PI23/01470
Duration: 01/01/2024 - 31/12/2026

Recerca biomèdica en ginecologia

IP: Antonio Gil Moreno
Collaborators: Natalia Rodriguez Gómez - Hidalgo, Elena Suarez Salvador, Jose Luis Poza Barrasus, Vicente Bebia Conesa, Angel García Jiménez, Maria Asuncion Perez Benavente, Carina Masferrer Ferragutcasas, Eva Colas Ortega, Sabina Salicrú Riera, Anna Ruano Lopez, Fco Javier De la Torre Fdez de Vega, Montserrat Cubo Abert, Silvia Cabrera Diaz, Laura Mañalich Barrachina, Marta Rebull Santamaria, Mireia Armengol Alsina, Ana Luzarraga Aznar, Irene De la Calle Fuentes, José Luis Sánchez Iglesias, Melissa Bradbury Lobato, Beatriz Villafranca Magdalena, Melek Denizli, Recerca biomèdica en ginecologia
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01157
Duration: 01/01/2022 - 30/06/2025

A dual liquid biopsy strategy in endometrial cancer: evaluation of risk of recurrence and pesonalized therapy.

IP: Antonio Gil Moreno
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Montserrat Cubo Abert, Mireia Armengol Alsina, Marta Rebull Santamaria, Melek Denizli
Funding agency: Instituto de Salud Carlos III
Funding: 209330
Reference: PI20/01566
Duration: 01/01/2021 - 31/12/2023

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Basilio Rodriguez  Diez

Basilio Rodriguez Diez

Senior researcher
Systemic Diseases
Read more
Laura Doménech Moral

Laura Doménech Moral

Main researcher
Basic, Translational and Clinical Pharmacy Research
Read more
José Raul Herance Camacho

José Raul Herance Camacho

Head of group
Molecular Medical Imaging
Read more
Jesús  Cirbián Franqueira

Jesús Cirbián Franqueira

Predoctoral researcher
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.